Italia markets closed

Dow Jones
38.802,74
+213,58(+0,55%)
Nasdaq
17.908,04
+219,16(+1,24%)
Nikkei 225
38.102,44
-712,12(-1,83%)
EUR/USD
1,0739
+0,0030(+0,28%)
Bitcoin EUR
62.554,51
+496,04(+0,80%)
CMC Crypto 200
1.398,44
+10,28(+0,74%)

NBIX Jul 2024 140.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

3,0100

0,0000

(0,00%)

In data: 01:23PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat